Research programme: cancer immunotherapies - Akriveia Therapeutics

Drug Profile

Research programme: cancer immunotherapies - Akriveia Therapeutics

Latest Information Update: 19 Oct 2016

Price : $50

At a glance

  • Originator Akriveia Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 12 Oct 2016 Early research in Cancer in USA
  • 12 Oct 2016 Akriveia Therapeutics, City of Hope and Thomas Jefferson University enter into license agreements for technologies for cancer immunotherapies in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top